Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Olema Oncology (Nasdaq: OLMA) announced it will present new data from its Phase 1b/2 clinical study at the San Antonio Breast Cancer Symposium (SABCS 2024). The study focuses on palazestrant (OP-1250) combined with CDK4/6 inhibitor ribociclib for treating ER+/HER2- advanced or metastatic breast cancer.
The poster presentation (ID: P2-09-16) is scheduled for December 11, 2024, from 5:30 to 7:00 p.m. CT in Halls 2-3. Olema will host an investor conference call on December 10, 2024, at 8:00 a.m. ET to discuss the findings. The poster will be available on Olema’s website following the symposium’s embargo policy.
Olema Oncology (Nasdaq: OLMA) ha annunciato che presenterà nuovi dati dal suo studio clinico di Fase 1b/2 al San Antonio Breast Cancer Symposium (SABCS 2024). Lo studio si concentra su palazestrant (OP-1250) combinato con l’inibitore CDK4/6 ribociclib per il trattamento di carcinoma mammario avanzato o metastatico ER+/HER2-.
La presentazione del poster (ID: P2-09-16) è programmata per l’11 dicembre 2024, dalle 17:30 alle 19:00 CT nelle sale 2-3. Olema ospiterà una teleconferenza per investitori il 10 dicembre 2024, alle 8:00 a.m. ET per discutere i risultati. Il poster sarà disponibile sul sito web di Olema secondo la politica di embargo del simposio.
Olema Oncology (Nasdaq: OLMA) anunció que presentará nuevos datos de su estudio clínico de Fase 1b/2 en el San Antonio Breast Cancer Symposium (SABCS 2024). El estudio se centra en palazestrant (OP-1250) combinado con el inhibidor de CDK4/6 ribociclib para tratar cáncer de mama avanzado o metastásico ER+/HER2-.
La presentación del póster (ID: P2-09-16) está programada para el 11 de diciembre de 2024, de 5:30 a 7:00 p.m. CT en los Salones 2-3. Olema llevará a cabo una llamada de conferencia para inversores el 10 de diciembre de 2024, a las 8:00 a.m. ET para discutir los hallazgos. El póster estará disponible en el sitio web de Olema siguiendo la política de embargo del simposio.
올레마 온콜로지 (Nasdaq: OLMA)가 2024년 샌안토니오 유방암 심포지엄 (SABCS 2024)에서 Fase 1b/2 임상 연구의 새로운 데이터를 발표할 것이라고 발표했습니다. 이 연구는 파라제스트란 (OP-1250)과 CDK4/6 억제제인 리복시클립을 병용하여 ER+/HER2- 진행성 또는 전이성 유방암을 치료하는 데 중점을 두고 있습니다.
포스터 발표 (ID: P2-09-16)는 2024년 12월 11일 오후 5:30부터 7:00까지 CT 시간에 2-3홀에서 예정되어 있습니다. 올레마는 2024년 12월 10일 오전 8:00 ET에 투자자 컨퍼런스 전화를 개최하여 연구 결과를 논의할 예정입니다. 포스터는 심포지엄의 엠바고 정책에 따라 올레마의 웹사이트에서 제공될 것입니다.
Olema Oncology (Nasdaq: OLMA) a annoncé qu’il présentera de nouvelles données de son étude clinique de Phase 1b/2 lors du San Antonio Breast Cancer Symposium (SABCS 2024). L’étude se concentre sur palazestrant (OP-1250) combiné avec l’inhibiteur CDK4/6 ribociclib pour traiter le cancer du sein avancé ou métastatique ER+/HER2-.
La présentation de l’affiche (ID: P2-09-16) est prévue pour le 11 décembre 2024, de 17h30 à 19h00 CT dans les Halls 2-3. Olema organisera une conférence téléphonique pour les investisseurs le 10 décembre 2024, à 8h00 ET pour discuter des résultats. L’affiche sera disponible sur le site Web d’Olema conformément à la politique d’embargo du symposium.
Olema Oncology (Nasdaq: OLMA) gab bekannt, dass es neue Daten aus seiner Phase 1b/2-Studie auf dem San Antonio Breast Cancer Symposium (SABCS 2024) präsentieren wird. Die Studie konzentriert sich auf Palazestrant (OP-1250), kombiniert mit dem CDK4/6-Inhibitor Ribociclib zur Behandlung von ER+/HER2- fortgeschrittenem oder metastasiertem Brustkrebs.
Die Posterpräsentation (ID: P2-09-16) ist für den 11. Dezember 2024, von 17:30 bis 19:00 Uhr CT in den Hallen 2-3, geplant. Olema wird am 10. Dezember 2024 um 8:00 Uhr ET eine Telefonkonferenz für Investoren abhalten, um die Ergebnisse zu besprechen. Das Poster wird gemäß der Embargopolitik des Symposiums auf der Website von Olema verfügbar sein.
Olema will host an investor conference call at 8:00 a.m. ET on December 10, 2024
SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that it will present new data from the Phase 1b/2 clinical study of palazestrant (OP-1250) in combination with CDK4/6 inhibitor ribociclib at the San Antonio Breast Cancer Symposium (SABCS 2024) being held December 10-13, 2024, at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
Poster Details
- Title: A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-), advanced or metastatic breast cancer
- Poster ID: P2-09-16
- Session: Poster Session 2
- Date/Time: Wednesday, December 11, 2024, from 5:30 to 7:00 p.m. CT
- Location: Halls 2-3
Additional information, including the abstract for this presentation, can be found on the SABCS website. A copy of the poster will be made available on the Publications page of Olema’s website in alignment with the Symposium’s embargo policy.
Conference Call Information
Olema will hold a conference call to discuss these data with the investment community on Tuesday, December 10, 2024, at 8:00 a.m. ET/7:00 a.m. CT. Register to join the webcast by visiting the Events page on the Investors and Media section of Olema’s website.
About Palazestrant (OP-1250)
Palazestrant (OP-1250) is a novel, orally available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD). It is currently being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In preclinical studies, palazestrant completely blocks ER-driven transcriptional activity in both ESR1 wild-type and mutant forms of breast cancer cell. In Olema’s ongoing clinical trials for advanced or metastatic ER+/HER2- breast cancer, palazestrant has demonstrated anti-tumor activity along with attractive pharmacokinetics and exposure, favorable tolerability, and combinability with CDK4/6 inhibitors. Palazestrant has been granted U.S. Food and Drug Administration (FDA) Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. It is being evaluated both as a single agent in an ongoing Phase 3 clinical trial, OPERA-01, and in Phase 1/2 combination studies with CDK4/6 inhibitors (palbociclib and ribociclib), a PI3Ka inhibitor (alpelisib), and an mTOR inhibitor (everolimus). For more information on OPERA-01, please visit www.opera01study.com.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.
Media and IR Contact
Courtney O’Konek
Vice President, Corporate Communications
media@olema.com
FAQ
When will Olema Oncology (OLMA) present its palazestrant combination therapy data at SABCS 2024?
Olema Oncology will present the data on Wednesday, December 11, 2024, from 5:30 to 7:00 p.m. CT during Poster Session 2 at SABCS 2024.
What type of breast cancer is Olema’s palazestrant combination therapy targeting?
The therapy targets estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer.
When is Olema Oncology’s (OLMA) investor conference call about the SABCS 2024 data?
Olema will hold an investor conference call on Tuesday, December 10, 2024, at 8:00 a.m. ET/7:00 a.m. CT.
What drug is being combined with palazestrant in Olema’s Phase 1b/2 study?
Palazestrant (OP-1250) is being combined with ribociclib, a CDK4/6 inhibitor, in the Phase 1b/2 study.
